Significantly mutated genes and regulatory pathways in SCLC—a meta-analysis

Publication date: October 2017
Source:Cancer Genetics, Volumes 216–217
Author(s): Varsha Sundaresan, Victor T. Lin, Faming Liang, Frederic J. Kaye, Reika Kawabata-Iwakawa, Kouya Shiraishi, Takashi Kohno, Jun Yokota, Lei Zhou
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers and demands effective targeted therapeutic strategies. In this meta-analysis study, we aim to identify significantly mutated genes and regulatory pathways to help us better understand the progression of SCLC and to identify potential biomarkers. Besides ranking genes based on their mutation frequencies, we sought to identify statistically significant mutations in SCLC with the MutSigCV software. Our analysis identified several genes with relatively low mutation frequency, including PTEN, as highly significant (p < 0.001), suggesting these genes may play an important role in the progression of SCLC. Our results also indicated mutations in genes involved in the axon guidance pathways likely play an important role in SCLC progression. In addition, we observed that the mutation rate was significantly higher in samples with RB1 gene mutated when compared to samples with wild type RB1, suggesting that RB1 status has significant impact on the mutation profile and disease progression in SCLC.



http://ift.tt/2tZz62F